RBM22P1

Across TCGA pan-cancer cohorts, RBM22P1 RNA is linked to patient survival in 9 of 34 cancer types, making it the most broadly survival-associated RBM22P1 data layer.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher RBM22P1 RNA is associated with worse overall survival. In most high-consensus cancer types, elevated RBM22P1 expression acts as an unfavorable survival marker, although some lineages such as ESCA and LUSC show a favorable association.

LUAD, SKCM, and SARC are the cancer types where RBM22P1 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Tertile	All	0.113	0.788	<.001	96	view →
SKCM	OS	Tertile	All	0.552	0.794	<.001	75	view →
SARC	DFS	Tertile	All	0.195	0.524	<.001	39	view →
UCEC	DFS	Tertile	All	0.809	0.904	.005	24	view →
KIRP	DFS	Tertile	All	0.462	0.878	.001	24	view →
GBM	OS	Tertile	All	0.069	0.415	<.001	18	view →
TGCT	DFS	Tertile	III,IV	0.017	0.923	.021	18	view →
ESCA	OS	Tertile	All	0.842	0.640	.018	15	view →
LUSC	OS	Tertile	II,III,IV	1.000	0.594	.032	9	view →

Pink = unfavorable, green = favorable. Showing the 9 strongest of 9 lineages.

RBM22P1–LUAD (OS)

Open the LUAD breakdown →